Voglibose

Voglibose

Systematic (IUPAC) name
(1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetraol
Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy cat.	?
Legal status	?
Identifiers
CAS number	83480-29-9 Y
ATC code	A10BF03
PubChem	CID 444020
DrugBank	DB04878
ChemSpider	392046 Y
UNII	S77P977AG8 Y
KEGG	D01665 Y
ChEMBL	CHEMBL476960 Y
Chemical data
Formula	C10H21NO7
Mol. mass	267.28 g/mol
SMILES	eMolecules & PubChem
InChI InChI=1S/C10H21NO7/c12-2-5(3-13)11-6-1-10(18,4-14)9(17)8(16)7(6)15/h5-9,11-18H,1-4H2/t6-,7-,8+,9-,10-/m0/s1 Y Key:FZNCGRZWXLXZSZ-CIQUZCHMSA-N Y
Y(what is this?)  (verify)

Voglibose (INN and USAN, trade name Voglib, marketed by Mascot Health Series) is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. Voglibose delays the absorption of glucose thereby reduces the risk of macrovascular complications. Voglibose is a research product of Takeda Pharma , A Japan based company.

Postprandial hyperglycemia (PPHG) is primarily due to first phase insulin secretion. Alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal.

There are three drugs which belong to this class, acarbose, miglitol and voglibose, of which voglibose is the newest. Voglibose scores over both acarbose and miglitol in terms of side effect profile. But acarbose has an edge over voglibose in terms of efficacy (FPG, PPHG, HBA_1c).

There are several trials supporting the use of voglibose in the management of PPHG. Also, it has been established that it is PPHG, not FPG, which is the marker of cardiovascular disorders associated with diabetes. So, controlling PPHG is imperative and voglibose is indicated for the management of PPHG.

External links

• diabetesincontrol.com
• diabetesjournals.org
• Ranbaxy announcement